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Background: After successful trials of tracheal reconstruction using mesh-type prostheses in canine models, the
technique has been applied clinically to human patients since 2002. To enhance tissue regeneration, we have
applied a new tissue engineering approach to this mesh-type prosthesis.
Methods: The prosthesis consists of a polypropylene mesh tube reinforced with a polypropylene spiral and ate-
locollagen layer. The cervical tracheas of 18 beagle dogs were replaced with the prosthesis. The collagen layer
was soaked with peripheral blood in 6 of the dogs, with bone marrow aspirate in another 6, and with autologous
multipotential bone marrow–derived cells (mesenchymal stem cells) in another 6. The dogs were humanely killed
at 1 to 12 months after the operation.
Results: All 18 dogs survived the postoperative period. Bronchoscopically, 3 of 4 dogs in the peripheral blood
group showed stenosis, whereas no stenosis was evident in all 8 of the dogs in the bone marrow and mesenchymal
stem cell groups 6 months after the operation. Faster epithelialization and fewer complications, such as mesh
exposure and luminal stenosis, were observed in these two groups than in the peripheral blood group. Histolog-
ically, the cells from autologous bone marrow were found to proliferate into the tracheal tissue during the first
month. Cilial movement in these two groups was faster than that in the peripheral blood group and recovered
to 80% to 90% of the normal level.
Conclusions: Bone marrow aspirate and mesenchymal stem cells enhance the regeneration of the tracheal
mucosa on this prosthesis. This in situ tissue engineering approach may facilitate tracheal reconstruction in the
clinical setting.End-to-end anastomosis has been the standard clinical
method for tracheal reconstruction since the 1970s.1 How-
ever, in cases in which the resected segment is more than
6 cm long, high tension at the anastomosis site can some-
times cause severe and fatal postoperative complications
such as dehiscence.2 A variety of artificial tracheas have
been designed for such cases and assessed, but so far none
has proved satisfactory for clinical use.
We have developed a new mesh-type tracheal prosthesis
on which autologous tracheal tissue is encouraged to regen-
erate on a collagen scaffold. We have already demonstrated
that this prosthesis can be applied safely for circumferential
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carinal bifurcation5 in canine models. On the basis of the suc-
cess of these experimental animal studies, clinical applica-
tion of the tracheal prosthesis was begun for human
patients with tracheal defects in 2002.6
In animal experiments, the initial type of prosthesis that
was simply coated with amorphous collagen often developed
mesh exposure or ulcers on the inner mucosa.7 This indicated
that early epithelial regeneration was a key factor required for
successful use of this mesh-type tracheal prosthesis. In other
words, enhancement of tissue recovery on the prosthesis was
a crucial requirement for tracheal reconstruction.
In clinical trials, the prosthesis was moistened with autolo-
gous peripheral blood before anastomosis.6 If tissue regenera-
tion can be facilitated with an improved method, it would
certainly contribute to the clinical feasibility of a tracheal pros-
thesis. Therefore, in the present study, we also used bone mar-
row aspirate and a suspension of bone marrow–derived
mesenchymal stem cells (MSCs) as alternatives to peripheral
blood. We also determined whether the seeded autologous
bone marrow cells proliferated into the tracheal tissue in situ.
MATERIALS AND METHODS
Collagen
The collagen used was extracted from skin of young pigs (6 months old
weighing about 120 kg) (supplied by Nippon Meatpackers Inc, Ibaraki,
Japan). The extracted collagen was then digested with pepsin at 4C forardiovascular Surgery c Volume 138, Number 4 811
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MRI ¼ magnetic resonance imaging
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48 hours. The supernatant consisted of type 1 collagen (70%–80%), and
the rest was type 3 collagen, as confirmed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. During the pepsin treatment, the
telopeptide of collagen, which is thought to have antigenicity, was removed,
leaving only the atelocollagen.
Prosthesis
A straight tube 16 mm in diameter was manufactured from a sheet of poly-
propylene mesh with a pore size of 260 3 106 m (Bard mesh; Davol Inc,
Cranston, RI) by melting the edges together. The tube was then reinforced
with a polypropylene monofilament yarn (0.8 mm in diameter) (Figure 1).
The yarn was spirally attached to the external surface of the mesh tube by
thermal melt-bonding at 5-mm intervals and further fixed with 7-0 Prolene
polypropylene suture (Ethicon, Inc, Somerville, NJ). The polypropylene
spiral provided the tube with stiffness against compression. The interval of
the yarn was determined so that the mechanical resistance against compres-
sion was the same as that of the native trachea.8
This polypropylene tube was then exposed to a coronal discharge at 9 kV
for 10 minutes to activate the surface. The prosthesis was subsequently
coated 10 times with the 1% collagen solution. The activated prosthesis
was covalently immobilized with collagen molecules and then further phys-
ically coated with collagen to promote host tissue incorporation and render
the prosthesis airtight during the initial stage of implantation. This coating
process was repeated 20 times.
The collagen-coated prosthesis was placed in a cylindrical Teflon mold
with an inner diameter of 37 mm and a depth of 6 cm. At the same time,
a 5-mm–diameter Teflon tube was inserted into the center of the prosthesis.
The 1% collagen solution, which had been stirred at 8000 rpm for
15 minutes, was poured into the space between the outer mold and the inner
tube and then freeze-dried. In this freeze-drying process, the cast collagen
became a porous structure with a pore size range of 100 to 500 3 106 m.
Finally, the prosthesis was subjected to dehydrothermal treatment 140C
in vacuo for 24 hours to induce cross-links between the collagen molecules
to prevent early breakdown of the collagen in vivo.
Animal Experiments
Eighteen beagle dogs weighing between 8 and 14 kg were divided at
random into three groups. The cervical trachea was cut transversely 20
mm caudal to the thyroid cartilage, and a tracheal segment (40–50 mm)
including seven tracheal cartilages was removed with the animal under
general anesthesia. During the operation, the prosthesis was preclotted
with 5 mL of autologous peripheral blood in 8 of the dogs (peripheral blood
group). In another 8 dogs, the prosthesis was soaked with 5 mL of bone
marrow aspirate obtained from the femoral bone during the operation
(bone marrow group). In the remaining 8 dogs, from which bone marrow
aspirate had been taken and incubated in advance, the prosthesis was soaked
with an incubated bone marrow cell suspension (MSC group). In these 8
dogs of the MSC group, 2 mL of bone marrow aspirate was taken from
the femur 4 weeks before the operation. The bone marrow aspirate was
incubated with Dulbecco modified Eagle medium containing 10% fetal bo-
vine serum. The incubation medium was changed every 3 days from the fifth
day. Floating cells were removed when the medium was changed. Some
cells became attached to the bottom of the incubation bottle and proliferated.
These proliferated cells were detached with trypsin, and a suspension of
these cells (107) was used in the operating room.812 The Journal of Thoracic and Cardiovascular SurThe porous collagen layer inside and outside the lumen shrank in volume
on soaking. The prosthesis and the cut ends of the trachea were anastomosed
with 3-0 Vicryl (Ethicon) interrupted sutures, the cut ends of the tracheal
stumps being inserted into the prosthesis lumen (Figure 2). Neither omento-
pexy nor fibrin glue was used.
A 1000-mg dose of ampicillin was injected intramuscularly on the day of
the operation, and a 500-mg dose was administered orally every day for
1 month thereafter. Bronchial cleaning with a fiberscope was only per-
formed immediately after the operation on the same day. No additional
care other than routine management was provided for the animals.
Bronchoscopic Examinations and Cilial Beat
Frequency (CBF) Examination
A bronchofiberoscope (model BF1T20; Olympus Optical Co Ltd,
Tokyo, Japan) examination was performed periodically under general anes-
thesia with an intramuscular injection of ketamine hydrochloride (10 mg/kg)
FIGURE1. Mesh-type tracheal prosthesis. The framework is a polypropyl-
ene mesh tube reinforced with a spiral stent (right). Freeze-dried collagen
layers were made both inside and outside the framework as a scaffold of tis-
sue regeneration (left).
FIGURE 2. Intraoperative view of the reconstruction of a canine trachea
with the prosthesis. The prosthesis was soaked with each medium before
anastomosis. The prosthetic wall became airtight with this process.gery c October 2009
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STABLE 1. Results of tracheal reconstruction with prosthesis
Dog no. Soak medium Observation (mo) Incorporation to host Stenosis Erosion
1 Peripheral blood 1 þ  
2 Peripheral blood 3 þ  
3 Peripheral blood 6 þ  
4 Peripheral blood 6 þ þ 
5 Peripheral blood 12 þ þ þ
6 Peripheral blood 12 þ þ 
7 Bone marrow aspirate 1 þ  
8 Bone marrow aspirate 3 þ  
9 Bone marrow aspirate 6 þ  
10 Bone marrow aspirate 6 þ  
11 Bone marrow aspirate 12 þ  
12 Bone marrow aspirate 12 þ þ 
13 MSC suspension* 1 þ  
14 MSC suspension 3 þ  
15 MSC suspension 6 þ  
16 MSC suspension 6 þ  
17 MSC suspension 12 þ  
18 MSC suspension 12 þ þ 
Mesenchymal stem cells (MSC) were labeled with fluorescent marker DiI. *Stenosis is defined as a reduction of the tracheal lumen by more than one third.and xylazine hydrochloride (4 mg/kg) to examine the luminal surface of the
prosthesis. The replaced segments were examined carefully. Mesh exposure
exceeding one third of the circumference was define as ‘‘þþ’’ and less than
one third as ‘‘þ.’’ Stenosis was defined as a reduction of more than one third
of inner luminal area.
At 6 months and 12 months, samples of the tracheal epithelium were re-
moved with a brush inserted through the channel of the bronchoscope to
evaluate cilial movement. The brush, which scrubbed the target (recon-
structed) portion of the tracheal mucosa, was washed with culture medium.
This medium (containing the scrubbed tracheal mucosa cells) dropped on
a glass slide was then observed with a light microscope. The movement
of the cilia on the slide was counted at 37C with a photomultiplier system9
connected to the microscope.
Cilial movement frequency was compared among the three groups by
analysis of variance and a t test. All frequency measurements obtained are
expressed as the mean ( standard deviation) of at least 10 determinations.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) of the reconstructed trachea and ad-
jacent organs was conducted on 1 dog from each group 12 months after im-
plantation. The MRI system used was a Sonata MRI System with a static
magnetic flux density of 1.5 T (Siemens Medical System, Erlangen,
Germany) using a phase-array body coil with four active segments. The
dog was anesthetized with an intravenous injection of propofol (Diprivan;
5 mg $ min1 $ kg1) during the imaging.
Histologic Examination
One dog in each group was humanely killed with an injected overdose of
sodium pentobarbital 1 and 3 months after tracheal reconstruction. Two dogs
in each group were humanely killed 6 months after tracheal reconstruction.
At 12 months, 2 dogs in the peripheral blood group and 1 each in the bone mar-
row and MSC groups were humanely killed. The remaining dog in each of the
bone marrow and MSC groups was allowed to survive for further observation.
En bloc resection of the prosthesis with the native trachea was carried out for
histopathologic evaluation. The epithelial cells on the inner surface were checked
with a scanning electron microscope (S-450; Hitachi Ltd, Tokyo, Japan).
All of the surgical and euthanasia procedures were performed in accor-
dance with the ‘‘Guide for the Care and Use of Laboratory Animals’’ pub-The Journal of Thoracic and Clished by the National Institutes of Health (NIH Publication No. 85-23,
revised 1985). The experimental protocol was approved by Animal Exper-
imental Committee of Kyoto University.
RESULTS
All animals in the three groups had uneventful postoper-
ative courses, and no symptoms that necessitated unsched-
uled humane killing of an animal occurred (Table 1).
Bronchoscopic Examination
Bronchoscopic examinations at 1 month revealed that the
luminal surface of the implanted prosthesis appeared glossy
and whitish, suggesting complete coverage of the lumen by
regenerated tissue (Figure 3). No mesh exposure was recog-
nized even in the middle of the prosthesis, except in 1 dog
(Table 1, dog 5), in which an area of exposed mesh measur-
ing about 5 3 2 mm was observed at the center of the pros-
thesis at 1 month. Despite this mesh exposure, the dog was
asymptomatic and its general condition was good, and no
retention of sputum was observed in the lumen of the pros-
thesis up to 12 months. Stenosis of the prosthetic lumen was
observed in 3 of the dogs in the peripheral blood group
and in 1 dog in each of the other two groups. This stenosis
occurred in the middle of the prosthesis and not at the sites
of anastomosis. The definition of stenosis used in this study
was reduction of the tracheal luminal diameter by more than
one third. Whereas both dogs in the bone marrow group and
the MSC group had only mild stenosis, severe stenosis that
reduced the diameter of the tracheal lumen by more than half
occurred in 3 of the 4 dogs in the peripheral blood group.
The narrowest luminal diameter was 9 mm in both the
bone marrow group and the MSC group, whereas that in
the peripheral blood group was 6 mm.ardiovascular Surgery c Volume 138, Number 4 813
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SFIGURE 3. Bronchoscopic views of the reconstructed site of the bone marrow group (dog 11) 1 month (left) and 12 months (right) after the operation.
Neither stenosis nor granulation is evident at the site of anastomosis with the trachea. Complete coverage of the mesh by regenerated tissue is evident.Macroscopic Examination
At 1 month the inner surface of the prosthesis was covered
with glossy tissue in all three groups (Figure 4). The prosthe-
ses were incorporated into the native tracheas, and there were
no major complications such as erosion of the surrounding
organs, abscess formation, pneumothorax, anastomotic de-
hiscence, or prosthetic dislocation in any of the 18 dogs
that were humanely killed on schedule (Table 1).
MRI
MRI at 12 months indicated no scar formation around the
prosthesis, and the inner lumen of the tube was maintained in
the cervical space in all three groups (Figure 5). The im-
planted prostheses were well incorporated with the native tra-
chea at the interfaces, and there was no morbid tissue reaction
between adjacent organs including major blood vessels.
Histologic Examinations
Examination with a light microscope at 1 month revealed
that the polypropylene mesh and polypropylene spiral had
become buried in newly regenerated connective tissue and
that the implanted collagen had disappeared. Capillary in-
growth was observed in the regenerated tracheal tissue in
all dogs of the three groups. After 6 months, formation of
respiratory epithelium was confirmed histologically from814 The Journal of Thoracic and Cardiovascular Surthe upper to the lower anastomotic site of the prosthesis
(Figure 6).
Although the extent of the epithelial lining of the regener-
ated mucosa on the prosthesis varied, 9 of the 12 dogs in the
bone marrow and MSC groups had an epithelial lining cov-
ering more than 50% of the length of the prosthesis. In con-
trast, after 3 and 6 months, the peripheral blood group had
poor epithelial lining, in which the squamous epithelium
was thicker than that of the columnar bronchial epithelium.
After 12 months, the extent of the epithelial lining in the pe-
ripheral blood group was similar to that in the other two
groups. In each animal, ciliated columnar epithelium was
observed near the anastomoses, the proportion of nonciliated
cuboidal epithelium increased with distance from the anasto-
moses, and squamous epithelium was observed in the center
of the prosthesis (Figure 7).
An area of exposed mesh measuring 5 3 2 mm without
any sign of local infection was observed in dog 5 of the pe-
ripheral blood group. No granulation tissue formation was
detected in the lumen.
Histologic examination of the stenotic part of the prosthe-
sis in 5 dogs showed that the connective tissue, including
vessels, had invaded the mesh pores, covering the inner sur-
face of the prosthesis. Also in these animals, the neoepithe-
lium appeared stretched from the cut end of the tracheal
stump over the connective tissue layer.FIGURE 4. Luminal surface of the prosthesis (bone marrow group, dog 8). Three months after reconstruction, the prosthesis was incorporated into the native
tracheas and inner surface was covered with glossy and whitish tissue. Polypropylene stents were seen in the cross-section of the reconstructed tracheal wall.gery c October 2009
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SScanning electron microscopy examination revealed that
the regenerated epithelial cells near the anastomoses pos-
sessed cilia similar to those of the normal tracheal epithelium
in all groups. Moreover, a few ciliated epithelial cells were
observed in areas where only a squamous cell lining was
demonstrated by light microscopy (Figure 7).
Observation by transmission electron microscopy showed
long and uniform cilia on the luminal surface over a large
area, gathering closely together (Figure 8) on the regenerated
part of the trachea in all three groups. In the area where cil-
iated cells were absent, the luminal surface was covered with
the squamous cells.
Comparison of CBF in the Regenerated Mucosa
CBF in the regenerated tracheal mucosa is shown in
Figure 9. CBF of the same portion of the trachea measured
in intact normal beagle dogs using the same system was
14.6  3.5.
At 6 months, CBF values in the bone marrow group and
MSC group had recovered to almost the normal range and
were significantly higher than that in the control group.
There were no significant differences in CBF among the
three groups at 12 months (P> .05).
FIGURE 5. MRI appearance of the prosthesis implanted into the cervical
trachea of a dog 12 months after the operation (MSC group). Replaced area
is indicated by the arrows.The Journal of Thoracic and CProliferation of Bone Marrow–Derived Cells
To determine the fate of the MSCs, we used MSC labeled
with Di-I (Cell Tracer CM-DiI; Molecular Probes, Leiden,
The Netherlands) in 1 dog (no. 13) of the MSC group, which
was killed 1 month after the operation. At this time, the Di-
I–labeled MSCs were recognized in the regenerated tracheal
tissue. They remained in the submucosal tissue around the
polypropylene mesh and were not present in the mucosa
(Figure 10).
DISCUSSION
Direct end-to-end anastomosis has been the ‘‘gold stan-
dard’’ for airway reconstruction.10 However, the range of
possible reconstruction with this method is limited, and
even within the feasible range (less than 6 cm), tension-
reducing procedures are required during the operation.
In the case of resections approaching the theoretical maxi-
mum, patients must endure a stressful drawn-in chin position
with neck fixation for at least 2 weeks after the operation to
avoid concentrating tension on the sites of anastomosis.2
Thus, direct apposition and suturing of the tracheal stumps
tends to place a heavy burden on the patient. For resolution
of such problems, the use of a tracheal substitute makes
reconstruction easier, and as a result, the surgical approach
can be expanded with the use of a tracheal prosthesis.
Many types of material have been examined for use in tra-
cheal prostheses since the first report by Daniel11 in 1948. A
prominent milestone in the history of artificial trachea devel-
opment was the introduction of a silicone rubber prosthesis in
the 1960s, which became commercially available in the
1970s12 and was used clinically for a short time. However,
because re-epithelialization could not be expected on the
FIGURE 6. Regenerated mucosa with epithelial lining on the mesh of the
prosthesis from a dog in the bone marrow group after 12 months. The mu-
cosa is thicker than the normal tracheal mucosa. L, Tracheal lumen; M, mesh
of the prosthesis (hematoxylin and eosin staining; original magnification,
3400).ardiovascular Surgery c Volume 138, Number 4 815
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SFIGURE 7. Ciliated epithelium is present on the regenerated mucosa near the anastomosis (upper left), but only squamous epithelium is present in the middle
of the prosthesis (upper right) in a dog in the bone marrow group after 12 months (hematoxylin and eosin staining; original magnification, 3200). Bottom,
Scanning electron microscopy (SEM) views of the luminal surface. Dense cilia like those of the normal tracheal epithelium are present on the prosthesis near
the anastomosis (lower left) and a few ciliated epithelial cells are present in areas where only a squamous cell lining was demonstrated by light microscopy
(lower right). Although these findings were evident in all three groups, there were more ciliated cells in the bone marrow and MSC groups than in the pe-
ripheral blood group.inner lumen, formation of granulation tissue or dehiscence
occurred at the interface between the prosthesis and the
native trachea, usually within several months.13 For this rea-
son, the nonporous tracheal prosthesis is now seldom used
clinically.
One of the reasons that prosthetic tracheal reconstruction
is more difficult than use of a vascular prosthesis may be that
the trachea is in contact with the external environment (ie, it
is an airway). At the interface of an implanted foreign body
and host tissue, the wound healing process continues until
the implanted foreign body is completely encapsulated or
is rejected from the implant site. Such phenomena are often
observed clinically by surgeons in relation to suture mate-
rials used on skin incisions. In this respect, an artificial tra-
chea contrasts conspicuously with an artificial vascular
graft, which has no external interface after implantation.
With this in mind, we3,4,7,8,14 have designed a series of
mesh-type tracheal prostheses that eliminate the interface
facing the airway. In such prostheses, autologous tissue
invades the pore spaces, and the interface of the foreign
material with the airway finally disappears with re-
epithelialization of the inner lumen.15
However, one problem with the mesh-type prosthesis that
needs to be overcome is insufficient air sealing of the mesh
structure, especially just after implantation. Indeed, to seal
the porous tracheal prosthesis, a 2-stage operation was once816 The Journal of Thoracic and Cardiovascular Surdesigned for ensuring that the prosthesis was airtight.16,17
However such a 2-stage operation places a heavy burden on
the patient and seems too complicated for clinical use.
Therefore, to seal the mesh, we14 began to apply collagen
in the early 1980s in the expectation that the collagen might
act not only as a palliative sealant but also as a scaffold for
tissue regeneration. Collagen, the main element of the extra-
cellular matrix, has been reported to play several important
roles in tissues, such as cell adhesion, detachment, transfor-
mation, and proliferation.18 For example, type 1 collagen is
reported to promote the differentiation of tracheal ciliated
epithelium.19
In this connection, tissue engineering, whereby a variety
of tissues can be fabricated in incubation rooms using cell
culture techniques, has been a focus of attention since
1990.20 Tissue engineering has also been applied for
tracheal reconstruction. In 1994, epithelial tissue was first
induced on a tissue-engineered trachea.21 In that study, tra-
cheal epithelial cells were isolated from newborn lambs in
advance to induce an epithelial lining on the reconstructed
site. These epithelial cells were injected into a previously
manufactured cylindrical cartilage tube made from cells har-
vested from calves. These in vitro–formed tubes were then
implanted into subcutaneous pockets of 10 nude mice,
aged 6 weeks. Four of the 10 implanted tubes were found
to develop an epithelial lining on the inner surface, whereasgery c October 2009
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MSC group (A). In the area where ciliated cells were absent, the luminal surface was covered with the squamous cells (B).the other 6 tubes became infected. In 2001, in vitro–cultured
tracheal epithelial cells were successfully transplanted onto
a prefabricated capsule pouch surface with fibrin glue for
possible use in tracheal reconstruction.22
Development of tracheal cartilage has also been studied
in rats by means of tissue engineering.23 Kojima and co-
workers24 have successfully constructed an autologous
tissue–engineered trachea with sheep nasal chondrocytes
and used it to reconstruct the trachea of 6 sheep. However,
because of malacia and stenosis, their animals survived
only 2 to 7 days after surgery. Okamoto and coworkers25
have made tracheal cartilage using bone morphogenetic
protein 2 in dogs. In their canine model, a 1 3 5-cm slit
defect of the tracheal cartilage was created in the trachea
in advance, while carefully preserving the tracheal mucosa.
Subsequently, regeneration of the cartilage was recognized
around the stumps of the resected cartilages. Although these
tissue engineering trials have met with some limited success,
achievement of a long-term durable tracheal cartilage with
mechanical properties similar to those of native tracheal car-
tilage still seems a long way off.
In situ tissue engineering is a novel method wherein tissue
is formed not in vitro previously, but in the patient’s body.26
FIGURE 9. Cilial beat frequency of the regenerated cilia. MSC, Mesen-
chymal blood cell.The Journal of Thoracic and CThat is to say, in conventional tissue engineering, a required
tissue has to be made previously on an incubation dish in the
laboratory room. By contrast, in in situ tissue engineering,
a scaffold of tissue is placed directly at the site of a tissue de-
fect in the body where regeneration of the tissue is required.
In our early experiment, in which a prototype Y-shaped
tracheal prosthesis was simply coated with amorphous colla-
gen alone, 13 of 20 dogs died within 11 days after tracheal
reconstruction.7 The main reason for these early postopera-
tive deaths was air leakage from the trunk of the prosthesis.
To address this problem, we27 improved the structure of
the tracheal wall by increasing the amount of collagen
through introduction of a porous collagen layer that was
laid over the amorphous collagen layer. This improvement
made the surgical procedure easier, and neither fibrin glue
nor pledget sealing was necessary at the anastomosis sites
during the operation.
For evaluation of functional recovery of the reconstructed
tracheal wall, we measured the CBF of the regenerated
FIGURE 10. Microscopic appearance of the regenerated part of the tra-
cheal wall after 1 month, showing numerous seeding MSCs, which are la-
beled with FM-DiI fluorescent tracer (original magnification, 3100). The
labeled cells remained in the submucosa tissue around the polypropylene
mesh and did not exist in the mucosa. M, Mesh of the prosthesis).ardiovascular Surgery c Volume 138, Number 4 817
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Stracheal epithelium. Cilia play a major role in preserving the
functional integrity of the airway, and CBF has been used as
a marker of tracheal function in the field of pulmonology.28
The CBF value of the regenerated cilial area was 80% to
90% of the normal value in the bone marrow and MSC
groups at 6 months and significantly higher than that in
the peripheral blood group, although by 12 months the dif-
ference among the three groups was not significant. This
may indicate that the reconstructed area had recovered not
only morphologically but also functionally.
In our previous series of experiments, we2-6 had soaked
the collagen sponge of the prosthesis with peripheral blood
during the operation. Because collagen has high affinity for
platelets,29 we expected that the platelets attached to the col-
lagen might provide platelet-derived growth factor or other
active molecules that would help to enhance tissue regener-
ation. In the present study, in addition to peripheral blood
used previously, we applied two other types of soaking me-
dium: a bone marrow aspirate and a suspension of incubated
bone marrow–derived cells. The latter cells have a tendency
to attach to the bottom of the incubation bottle. Inasmuch as
these cells have the potential to differentiate into several
types of mesenchymal tissue, such as muscle, fat, and
bone, they have been called multipotential bone marrow–
derived cells or MSCs.30 These cells have already been
applied clinically as a cell source for tissue engineering.31
The results obtained in the bone marrow aspirate and
MSC groups were better than those in the peripheral blood
group. Mesh exposure and luminal stenosis occurred in
only 2 dogs of the former two groups. These complications
were milder in degree than those in the peripheral blood
group. There was no significant difference in performance
between the bone marrow aspirate group and the MSC
group. In contrast, in the peripheral blood group, small areas
of either mesh exposure or luminal stenosis occurred in all of
the dogs but did not threaten the general condition of the an-
imals or cause any significant problems. Evaluation of the
functional recovery of the reconstructed site in terms of cilial
movement revealed a similar tendency. Therefore, the appli-
cation of bone marrow and MSCs to our prosthesis seemed
to facilitate healing of the reconstructed tracheal region.
In the present study, we found that the implanted MSCs
proliferated into the tracheal tissue. However it still remains
unclear whether the cells in the soaked bone marrow aspirate
also proliferated into the tracheal tissue. It will also be nec-
essary to carry out further studies of the mechanism whereby
soaked cells assist in tracheal remodeling on the collagen
scaffold.
From a clinical viewpoint, use of a patient’s own bone
marrow aspirate seems to have many potential advantages.
Aspiration of 2 mL of bone marrow from an anesthetized
patient is relatively easy in the operating room and requires
no incubation process to encourage cell proliferation. Elim-
inating the use of fetal bovine serum also obviates the risk of818 The Journal of Thoracic and Cardiovascular Surother unknown viral infections. In this regard, the applica-
tion of MSCs in this experiment or iPS (induced pleuripo-
tent) stem cells drawing current interest of the world have
the same disadvantage; their clinical safety in terms of virus
infection or tumorigenicity has not been established, inas-
much as fetal bovine serum or other nonautologous sub-
stances are now indispensable for preparation of such
MSCs as well as iPS (induced pleuripotent) stem cells.32
In conclusion, although further long-term observation is
required, our tracheal prosthesis appears promising for the
repair of tracheal defects, and the application of autologous
bone marrow may be clinically most feasible to assist the
regeneration of tracheal tissue.
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